Choose life

The US life settlements sector is marketing itself to pension funds and European insurers as an easy way to add diversification to a portfolio. But how are the risks modelled and how can the banks and hedge funds that are brokering the transactions accurately measure longevity risk, a speciality of the ceding insurer? William Rhode reports

transfusion

The US life settlements market has been in the mainstream press for all the wrong reasons lately, with a series of sensational articles peppered with catchphrases such as Wall Street fat cats, death bonds, Aids viaticals and ghoulish investment schemes.

The reason for the sudden witch-hunt, it seems, is that life settlements are on the brink of securitisation, with an announcement by little-known Canadian rating agency DBRS that it may be close to rating a debt issue backed by a pool of life

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here